

32nd Ernst Klenk Symposium in Molecular Medicine

certified with
16 CME credits

Precision oncology: Translating basic discoveries into patient survival.

Dec. 08 -10, 2016 in Cologne



Anton Berns - Amsterdam, NL
Lukas E Dow - New York, US
Enriqueta Felip - Barcelona, ES
Gordon J Freeman - Boston, US
Mathew Garnett - Cambridge, UK
John G Gribben - London, UK
Michael Hölzel - Bonn, DE
Richard Marais - Manchester, UK

Matthew L Meyerson - Boston, US
Tony S K Mok - Hong Kong, HK
Pier P Pandolfi - Boston, US
William Pao - Basel, CH
Stefan Pfister - Heidelberg, DE
Neal Rosen - New York, US
Julien Sage - Stanford, US
Dieter Saur - Munich, DE

Dirk Schadendorf - Essen, DE
Clemens A Schmitt - Berlin, DE
William R Sellers - Cambridge, US
Jeffrey A Sosman - Chicago, US
Louis M Staudt - Bethesda, US
Thomas Tüting - Magdeburg, DE
E John Wherry - Philadelphia, US
Kwok K Wong - Boston, US

Ernst Klenk Lecture - Charles Swanton - London, UK

Scientific Coordination

Charles Swanton - London, UK

jointly with **H Christian Reinhardt** and **Roman Thomas** - Cologne, DE

Fritz Thyssen Stiftung
für Wissenschaftsförderung

Program and further information: www.cmmc-uni-koeln.de

Participation is free of charge - free registration required

Organized by

CMMC

CENTER FOR MOLECULAR MEDICINE COLOGNE

in association with: Center for Integrated Oncology • KFO 286 • CRC 1218 • CRC 829 • CRC 670 • Dept. of Translational Genomics • e:Med Systems Medicine • sybacol • ITN CodeAge • CECAD Cologne • Cologne Center for Genomics • Dept. I for Internal Medicine • Dept. for Pathology • Clinical Trials Centre Cologne • Univ. Hospital Cologne • BioRiver Life Science im Rheinland e.V. • Cologne Convention Bureau



Bristol-Myers Squibb



MERCK

janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson

Lilly

new oncology

abbvie